Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax Provisions
Others
Ratios

Tango Therapeutics (TNGX) Other Non Operating Income: 2020-2025

Historic Other Non Operating Income for Tango Therapeutics (TNGX) over the last 5 years, with Sep 2025 value amounting to $705,000.

  • Tango Therapeutics' Other Non Operating Income fell 63.96% to $705,000 in Q3 2025 from the same period last year, while for Sep 2025 it was $4.2 million, marking a year-over-year decrease of 49.18%. This contributed to the annual value of $7.6 million for FY2024, which is 28.05% up from last year.
  • As of Q3 2025, Tango Therapeutics' Other Non Operating Income stood at $705,000, which was down 22.53% from $910,000 recorded in Q2 2025.
  • In the past 5 years, Tango Therapeutics' Other Non Operating Income ranged from a high of $2.2 million in Q1 2024 and a low of -$81,000 during Q4 2021.
  • Its 3-year average for Other Non Operating Income is $1.5 million, with a median of $1.5 million in 2024.
  • Its Other Non Operating Income has fluctuated over the past 5 years, first plummeted by 4,150.00% in 2021, then spiked by 2,689.36% in 2023.
  • Tango Therapeutics' Other Non Operating Income (Quarterly) stood at -$81,000 in 2021, then soared by 1,293.83% to $967,000 in 2022, then soared by 113.13% to $2.1 million in 2023, then decreased by 28.38% to $1.5 million in 2024, then crashed by 63.96% to $705,000 in 2025.
  • Its Other Non Operating Income stands at $705,000 for Q3 2025, versus $910,000 for Q2 2025 and $1.1 million for Q1 2025.